Literature DB >> 25841257

Neuropathic pain: principles of diagnosis and treatment.

Ian Gilron1, Ralf Baron2, Troels Jensen3.   

Abstract

Neuropathic pain is caused by disease or injury of the nervous system and includes various chronic conditions that, together, affect up to 8% of the population. A substantial body of neuropathic pain research points to several important contributory mechanisms including aberrant ectopic activity in nociceptive nerves, peripheral and central sensitization, impaired inhibitory modulation, and pathological activation of microglia. Clinical evaluation of neuropathic pain requires a thorough history and physical examination to identify characteristic signs and symptoms. In many cases, other laboratory investigations and clinical neurophysiological testing may help identify the underlying etiology and guide treatment selection. Available treatments essentially provide only symptomatic relief and may include nonpharmacological, pharmacological, and interventional therapies. Most extensive evidence is available for pharmacological treatment, and currently recommended first-line treatments include antidepressants (tricyclic agents and serotonin-norepinephrine reuptake inhibitors) and anticonvulsants (gabapentin and pregabalin). Individualized multidisciplinary patient care is facilitated by careful consideration of pain-related disability (eg, depression and occupational dysfunction) as well as patient education; repeat follow-up and strategic referral to appropriate medical/surgical subspecialties; and physical and psychological therapies. In the near future, continued preclinical and clinical research and development are expected to lead to further advancements in the diagnosis and treatment of neuropathic pain.
Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25841257     DOI: 10.1016/j.mayocp.2015.01.018

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  121 in total

1.  Lateral Hypothalamic Stimulation Reduces Hyperalgesia Through Spinally Descending Orexin-A Neurons in Neuropathic Pain.

Authors:  Jacob Wardach; Monica Wagner; Younhee Jeong; Janean E Holden
Journal:  West J Nurs Res       Date:  2015-10-15       Impact factor: 1.967

Review 2.  TFOS DEWS II pain and sensation report.

Authors:  Carlos Belmonte; Jason J Nichols; Stephanie M Cox; James A Brock; Carolyn G Begley; David A Bereiter; Darlene A Dartt; Anat Galor; Pedram Hamrah; Jason J Ivanusic; Deborah S Jacobs; Nancy A McNamara; Mark I Rosenblatt; Fiona Stapleton; James S Wolffsohn
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

3.  LRP1 deficiency in microglia blocks neuro-inflammation in the spinal dorsal horn and neuropathic pain processing.

Authors:  Coralie Brifault; HyoJun Kwon; Wendy M Campana; Steven L Gonias
Journal:  Glia       Date:  2019-02-11       Impact factor: 7.452

Review 4.  [SCS as a treatment option for failed back surgery syndrome].

Authors:  V Tronnier
Journal:  Orthopade       Date:  2016-09       Impact factor: 1.087

5.  α-Spinasterol: a COX inhibitor and a transient receptor potential vanilloid 1 antagonist presents an antinociceptive effect in clinically relevant models of pain in mice.

Authors:  Indiara Brusco; Camila Camponogara; Fabiano Barbosa Carvalho; Maria Rosa Chitolina Schetinger; Mauro Schneider Oliveira; Gabriela Trevisan; Juliano Ferreira; Sara Marchesan Oliveira
Journal:  Br J Pharmacol       Date:  2017-10-18       Impact factor: 8.739

6.  sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.

Authors:  Dan Kaufmann; Peter J West; Misty D Smith; Boris Yagen; Meir Bialer; Marshall Devor; H Steve White; K C Brennan
Journal:  Pharmacol Res       Date:  2016-11-24       Impact factor: 7.658

7.  The antioxidant N-(2-mercaptopropionyl)-glycine (tiopronin) attenuates expression of neuropathic allodynia and hyperalgesia.

Authors:  Muhammad Shahid; Fazal Subhan; Nazar Ul Islam; Nisar Ahmad; Umar Farooq; Sudhair Abbas; Shehla Akbar; Ihsan Ullah; Naila Raziq; Zia Ud Din
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-20       Impact factor: 3.000

8.  Gamma-Decanolactone Alters the Expression of GluN2B, A1 Receptors, and COX-2 and Reduces DNA Damage in the PTZ-Induced Seizure Model After Subchronic Treatment in Mice.

Authors:  Fernanda Marcelia Dos Santos; Pricila Fernandes Pflüger; Leticia Lazzarotto; Mariana Uczay; Wesley Roberto de Aguida; Lisiane Santos da Silva; Fernanda Brião Menezes Boaretto; Jayne Torres de Sousa; Jaqueline Nascimento Picada; Iraci Lucena da Silva Torres; Patrícia Pereira
Journal:  Neurochem Res       Date:  2021-05-21       Impact factor: 3.996

Review 9.  Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith
Journal:  Semin Oncol Nurs       Date:  2019-04-30       Impact factor: 2.315

10.  Analyses of long non-coding RNA and mRNA profiles in the spinal cord of rats using RNA sequencing during the progression of neuropathic pain in an SNI model.

Authors:  Jun Zhou; Youling Fan; Hongtao Chen
Journal:  RNA Biol       Date:  2017-09-29       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.